OR WAIT null SECS
ClinPharm Consulting is offering new services to enable biopharmaceutical companies to reduce drug development risks and maximize return on R&D investment.
The services are derived from insights into preventable issues revealed by the firm’s clinical pharmacology and PK-PD work across numerous client projects.
“Our new services arise from important concepts that our clients are seeking, including sound strategic and scientific advice and rapid delivery of services at an affordable cost,” said ClinPharm Consulting’s Chief Scientific Officer, Bill Wargin, PhD, adding, “We’re developing proactive solutions to help avoid development delays for companies and maximize their return on R&D investment.”
The new services offered by ClinPharm Consulting include the following:
In addition to these new services, ClinPharm Consulting is seeing growing interest in customized clinical pharmacology plans to address important issues and prevent delays in clinical studies, providing a road map to clients’ programs and identifying key areas to avoid risk.